Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Pedram Kharaziha 1 , Dimitris Chioureas 1 , Dorothea Rutishauser 2, 3 , George Baltatzis 4 , Lena Lennartsson 1 , Pedro Fonseca 1 , Alireza Azimi 1 , Kjell Hultenby 5 , Roman Zubarev 2, 3 , Anders Ullén 1 , Jeffrey Yachnin 1 , Sten Nilsson 1 , Theocharis Panaretakis 1 1 Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden 2 Department of Medical Biochemistry and Biophysics, Karolinska Institutet and University Hospital, Stockholm, Sweden 3 Science for Life Laboratory, Stockholm, Sweden 4 Department of Medicine, School of Health Sciences, University of Athens, Athens, Greece 5 Department of Laboratory Medicine, Karolinska Institutet and University Hospital, Huddinge, Sweden Correspondence to: Theocharis Panaretakis, e-mail: theoharis.panaretakis@ki.se Keywords: Prostate cancer, exosomes, docetaxel, resistance, biomarkers Received: September 17, 2014 Accepted: January 27, 2015 Published: March 12, 2015 ABSTRACT Docetaxel is a cornerstone treatment for metastatic, castration resistant prostate cancer (CRPC) which remains a leading cause of cancer-related deaths, worldwide. The clinical usage of docetaxel has resulted in modest gains in survival, primarily due to the development of resistance. There are currently no clinical biomarkers available that predict whether a CRPC patient will respond or acquire resistance to this therapy. Comparative proteomics analysis of exosomes secreted from DU145 prostate cancer cells that are sensitive (DU145 Tax-Sen) or have acquired resistance (DU145 Tax-Res) to docetaxel, demonstrated significant differences in the amount of exosomes secreted and in their molecular composition. A panel of proteins was identified by proteomics to be differentially enriched in DU145 Tax-Res compared to DU145 Tax-Sen exosomes and was validated by western blotting. Importantly, we identified MDR-1, MDR-3, Endophilin-A2 and PABP4 that were enriched only in DU145 Tax-Res exosomes. We validated the presence of these proteins in the serum of a small cohort of patients. DU145 cells that have uptaken DU145 Tax-Res exosomes show properties of increased matrix degradation. In summary, exosomes derived from DU145 Tax-Res cells may be a valuable source of biomarkers for response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 12×
“We observed a good correlation to our cell line data, for MDR-1/3 and PABP4 that could mainly be detected in the EVs isolated from CRPC Tax-Res patients (Figure 5C).”
BackgroundInfluentialBerthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394 · cited 1×
“It acts by inhibiting CYP17, an important enzyme in the synthesis of androgens and estrogens and thereby prevents the bioavailability of androgen receptor substrates [28, 29].”
Background
Cited by
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Liquid biopsy: a step forward towards precision medicine in urologic malignancies
Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M. D., & Yousef, G. M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0644-5 · Cited by 330
Internalization of Exosomes through Receptor-Mediated Endocytosis
Gonda, A., Kabagwira, J., Senthil, G. N., & Wall, N. R. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0891 · Cited by 296
“While this group showed an indirect role the EGF/EGFR complex plays in enhancing macropinocytic uptake of exosomes, both EGFR and EGF have been identified on exosomal surfaces, indicating a potential direct role (138).”
BackgroundLiang, G., Kan, S., Zhu, Y., Feng, S., Feng, W., & Gao, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s154458 · Cited by 276
PIKfyve inhibition increases exosome release and induces secretory autophagy
Hessvik, N. P., Øverbye, A., Brech, A., Torgersen, M. L., Jakobsen, I. S., Sandvig, K., & Llorente, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2309-8 · Cited by 269
“Among the detected autophagosomal proteins only p62, TOLLIP and NBR1 have previously been described in exosomes [60, 61].”
Ribeiro-Rodrigues, T. M., Martins-Marques, T., Morel, S., Kwak, B. R., & Girão, H. (2017) · Journal of Cell Science · doi:10.1242/jcs.200667 · Cited by 203
“…attachment of small ubiquitin-like modifier (SUMO) to Cx43 results in its stabilization at the plasma membrane, with the consequent enhancement of gap junctionmediated intercellular communication (GJIC), as measured by an increased dye transfer between neighbouring cells (Kjenseth et al., 2012).”
BackgroundMetalloproteinases in extracellular vesicles
Shimoda, M., & Khokha, R. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.027 · Cited by 170
Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles
Sousa, D., Lima, R. T., & Vasconcelos, M. H. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.002 · Cited by 162
“P-gp was enriched in EVs shed by drug-resistant cells but not in EVs shed by drug-sensitive cells [19].”
BackgroundAdvances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Kharaziha, P., Chioureas, D., Rutishauser, D., Baltatzis, G., Lennartsson, L., Fonseca, P., Azimi, A., Hultenby, K., Zubarev, R., Ullén, A., Yachnin, J., Nilsson, S., & Panaretakis, T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-12
- Volume
- 6
- Issue
- 25
- Pages
- 21740-21754
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1902243229
- Cited by
- 149
- References
- 6
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.